Anti-obesity Drugs Market CAGR To Exceed 21% by 2035, Due to The Growing Need for Anti-obesity Drugs | Roots Analysis

According to our latest market report "Anti-obesity Drugs Market, till 2035 by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players: Industry Trends and Global Forecasts", the global anti-obesity drugs market size is projected to reach USD 104.9 billion by 2035 from USD 12.8 billion in 2024, growing at a CAGR of 21.1% in the forecast period.

To Request for free sample please visit : https://www.rootsanalysis.com/reports/anti-obesity-drugs-market/request-sample.html

Anti-obesity drugs include a range of pharmaceutical treatments designed to assist individuals in managing obesity and associated concerns of chronic disorders, such as diabetes mellitus and cardiovascular disorders. These medications enhance weight loss by influencing appetite regulation, fat absorption and metabolism. It is worth mentioning that in the recent years, several new anti-obesity drugs have received regulatory approval, expanding the options available to patients, offering alternatives to bariatric surgery. Additionally, the ongoing advancements in drug formulation and delivery systems, coupled with the development of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. Notably, the rise in telehealth services and digital therapeutics is further facilitating better patient engagement and adherence to the treatment regimens. Consequently, the aforementioned factors are likely to present lucrative market growth opportunities for drug developers and this domain is anticipated to experience enormous growth in the coming years.

Anti-obesity Drugs Market Segments

Based on the type of molecule, the market is segmented into biologics and small molecules

1. The small molecules segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
2. The biologics segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 23.8%, during the forecast period.

Based on the active compound used, the market is segmented into tirzepatide, semaglutide, retatrutide, survodutide, cagrilintide and semaglutide, orforglipron, liraglutide, other active compounds

1. The semaglutide segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
2. The tirzepatide segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.

Based on the mechanism of action, the market is segmented into GLP-1 agonists / GIP agonists, GLP-1 agonists / GCGR agonists, GLP-1 agonists, GLP-1 agonists / Amylin analogues, GLP-1 / GCGR / GIP agonists and other mechanisms of action

1. The GLP-1 agonists segment is likely to capture the largest revenue share of 65% in the anti-obesity drugs market in 2024.
2. The GLP-1 agonists / GIP agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.

Based on the type of agonist, the market is segmented into single-agonists, dual-agonists and tri-agonists

1. The single-agonists segment is likely to capture the largest revenue share of around 70% in the anti-obesity drugs market in 2024.
2. The dual-agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 25.7%, during the forecast period.

To request quote of this report, please visit
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market/request-quote.html

Based on the action pathway, the market is segmented into centrally acting, peripherally acting, centrally acting and peripherally acting drugs

1. The centrally acting drugs segment is likely to capture the largest revenue share of around 85% in the anti-obesity drugs market in 2024.
2. The centrally acting drugs segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.6%, during the forecast period.

Based on the route of administration, the market is segmented into oral and parenteral route of administration

1. The segment for parenteral route of administration is likely to capture the largest revenue share of more than 95% in the anti-obesity drugs market in 2024.
2. The segment for oral route of administration is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 40.6%, during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific and Latin America

1. North America is likely to dominate the anti-obesity drugs market, by capturing the largest revenue share of nearly 70%, in 2024.
2. In Asia-Pacific, the anti-obesity drugs market is likely to demonstrate considerable growth with a relatively higher CAGR (~40%) during the forecast period.

Anti-obesity Drugs Market Regional Outlook

Based on the geographical regions, the anti-obesity drugs market can be segmented into four major regions, including North America, Europe, Asia-Pacific and Latin America. North America is anticipated to capture the majority share of the anti-obesity drugs market in 2024. The advanced healthcare infrastructure and research capabilities in North America enable drug developers to conduct extensive clinical trials, which is necessary to meet the required regulatory guidelines provided by the approval bodies. Further, the anti-obesity drugs domain in Asia-Pacific is accounted to be the fastest-growing segment of the market.

Key Report Takeaways

1. Presently, around125 players are engaged in the development of anti-obesity drugs; of these, around 55% players are headquartered in North America
2. A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; followed by players (~20%) undertaking expansion initiatives
3. The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

Anti-obesity Drugs Market Key Players
Examples of key companies engaged in anti-obesity drugs market (which have also been profiled in this market report) include (in alphabetic order) Adocia, AstraZeneca, Boehringer Ingelheim, CinFina Pharma, Eli Lilly, Gmax Biopharma, Hanmi Pharm, Jiangsu Hengrui Pharmaceuticals, Kallyope, Novo Nordisk, PegBio. Pfizer, QL Biopharm, Regeneron, Roche, Sciwind Biosciences, Viking Therapeutics and Zealand Pharma

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.